Novo Nordisk 'B'

Novo Nordisk said it will rebrand to "Novo" and implement a cultural overhaul under CEO Mike Doustdar to accelerate decision‑making, R&D, manufacturing and commercial execution as it faces stronger competition from Eli Lilly. The company outlined four new operating principles and will detail strategic changes at its Capital Markets Day on Sept. 21. Novo reported a lagging obesity market share (38.8% vs Lilly's 60.9% in Q2) despite strong uptake of oral Wegovy, and said the legal name Novo Nordisk will remain in use. » Więcej na cnbc.com

Novo Nordisk is rebranding under the single name "Novo" with the slogan "Lasting Health Starts Now" and introducing "The Novo Way," four cultural principles aimed at speeding decision-making and customer focus. The move seeks to close a widening gap with Eli Lilly, which held 60.9% of the obesity drug market versus Novo's 38.8% in Q2. Novo also disclosed a late-stage cardiovascular drug failure for ziltivekimab, said the oral Wegovy has passed 3 million prescriptions through June, and will present a detailed strategy at a Capital Markets Day on September 21 in London. » Więcej na finance.yahoo.com

Novo Nordisk will present itself as Novo in day-to-day business going forward and has refreshed its logo to make the brand more visible. The company says the slimmer name and a cultural shift are intended to strengthen consumer outreach and improve competitiveness against Eli Lilly. CEO Mike Doustdar will unveil the next phase of the comeback plan on Sept. 21; Novo benefits from strong demand for the Wegovy pill but faces investor concerns after disappointing data on some pipeline projects. » Więcej na finanzen.net